afatinib Non-small cell lung cancer: just another 'tinib'

首页> 外文期刊>Prescrire international >afatinib Non-small cell lung cancer: just another 'tinib'

【24h】

afatinib Non-small cell lung cancer: just another 'tinib'

机译：阿法替尼非小细胞肺癌：另一个“替尼”

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

In patients with inoperable or metas-tatic non-small cell lung cancer carrying activating EGFR (epidermal growth factor receptor) gene mutations, there is no evidence that gefitinib and eriotinib, two EGFR tyrosine kinase inhibitors, provide a survival advantage compared to platinum- or docefaxe/-based chemotherapy. They do, however, have different adverse effect profiles. Afatinib (Giotrif, Boehringer Ingelheim) is a weakly specific inhibitor of EGFR tyrosine kinase activity. It has been authorised in the European Union for the treatment of patients with locally advanced or metastatic non-small cell lung cancer carrying an activating EGFR mutation who have never previously received an EGFR tyrosine kinase inhibitor.

机译：对于携带激活的EGFR（表皮生长因子受体）基因突变的无法手术或转移的非小细胞肺癌患者，没有证据表明吉非替尼和埃罗替尼是两种EGFR酪氨酸激酶抑制剂，与铂类或铂类相比，具有生存优势。 docefaxe /基于化学疗法。但是，它们确实具有不同的不良影响。阿法替尼（Giotrif，Boehringer Ingelheim）是EGFR酪氨酸激酶活性的弱特异性抑制剂。它已获得欧盟的批准，可用于治疗患有局部晚期或转移性非小细胞肺癌的患者，这些患者携带激活的EGFR突变，以前从未接受过EGFR酪氨酸激酶抑制剂。

著录项

来源
《Prescrire international》 |2015年第160期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. afatinib Non-small cell lung cancer: just another "tinib" [J] . Prescrire international . 2015,第160期

机译：阿法替尼非小细胞肺癌：另一个“替尼”
2. Prolonged Survival in a Non-Small Cell Lung Cancer with Brain Metastasis Treated with a Brain Mass Evacuation and Gefi tinib [J] . Mardiah Suci Hardianti, Johan Kurnianda Acta Interna: The Journal of Internal Medicine . 2015,第1期

机译：脑转移瘤和吉非替尼治疗非小细胞肺癌脑转移患者的生存期延长
3. Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR -Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601) [J] . Atsushi Nakamura, Shunichi Sugawara, Hisashi Tanaka, The oncologist . 2020,第10期

机译：EGFR型非小细胞肺癌患者低剂量AFATINIB维持治疗的II期研究：北日本肺癌研究组试验1601（NJLCG1601）
4. A Deep Learning-Facilitated Radiomics Solution for the Prediction of Lung Lesion Shrinkage in Non-Small Cell Lung Cancer Trials [C] . Antong Chen, Jennifer Saouaf, Bo Zhou, IEEE International Symposium on Biomedical Imaging . 2020

机译：在非小细胞肺癌试验中用于预测肺病变萎缩的深度学习促进放射组学解决方案
5. The role of NAD(P)H:quinone oxidoreductase 1 in non-small cell lung cancer tumorigenesis and lung cancer stem cell maintenance [D] . Madajewski, Brian. 2016

机译：NAD（P）H：醌氧化还原酶1在非小细胞肺癌的发生和肺癌干细胞维持中的作用
6. Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer [O] . Youngjoo Lee, Ki Hyeong Lee, Geon Kook Lee, 2017

机译：阿法替尼联合辛伐他汀与单独的阿法替尼单独进行II期随机治疗的晚期非腺癌非小细胞肺癌患者
7. Afatinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) who are refractory to erlotinib/gefitinib and afatinib monotherapy [O] . Grössmann N. 2016

机译：非小细胞肺癌（NSCLC）患者的阿法替尼（Giotrif®）对厄洛替尼/吉非替尼和阿法替尼单药治疗无效

afatinib Non-small cell lung cancer: just another 'tinib'

摘要

著录项

相似文献

相关主题

期刊订阅